|Elimination half-life||12.5 hours|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||410.42 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Darusentan (LU-135252; HMR-4005) is an endothelin receptor antagonist. Gilead Colorado, a subsidiary of Gilead Sciences, under license from Abbott Laboratories, is developing darusentan for the potential treatment of uncontrolled hypertension.
In June 2003, Myogen licensed the compound from Abbott for its application in the cancer field.
In May 2007, a randomized, double-blind, active control, parallel assignment, safety and efficacy phase III trial was initiated in subjects who had completed the maintenance period of the DAR-312 study.
|This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|